PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Unice; U.S. DEPARTMENT OF COMMERCE a Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 2

Complete if Known				
Application Number	10/809,060			
Filing Date	March 25, 2004			
First Named Inventor	Heinz-Gerd Klaes			
Art Unit	1623			
Examiner Name	To be assigned			
Attorney Docket Number	1/1475			

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
7		^{US-} 6,147,095	11/14/2000	James J. Ferry et al		
1		US-				
		US-				
		US-				
······		US-				
		US-				
		US-				
		ÚS-				
		us-				
		US-	<u> </u>			
		us-				
	· 	us-				
		US-				
		US-				
		US-				
		US-				
		US-	· · · · · · · · · · · · · · · · · · ·			
	l	US-				

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Mind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T°	
RZ		WO 99/09031	02/25/1999	Medivir AB	or Relevant Figures Appear	H	
	······	WO 99/41268	08/19/1999	Medivir AB	***************************************		
ľ		WO 91/01137	02/07/1991	Harmenberg, Johan			
V		WO 88/00050	01/14/1988	Astra Lakemedel Aktiebolag			
PL		WO 00/51641	09/08/2000	Biochem Pharma Inc.			

Examiner Signature	Matria L	Date Considered	7-26-05

*EXAMINER: Idial if release considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Trainstation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO					Complete if Known		
					Application Number	10/809,060	
	INFOF	RMATION DI	ISCLO	SURE	Filing Date	March 25, 2004	
,	STATEMENT BY APPLICANT			CANT	First Named Inventor	Heinz-Gerd Klaes	
					Art Unit	1623	· <u> </u>
		(Use as many sheets as	в песеввагу)	Examiner Name	To be assigned	
	Sheet	2	of	2	Attorney Docket Number	1/1475	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
PL		ROY M. GULICK ET AL; New drugs for HIV therapy; AIDS (2002) Vol. 16 No. 4 pages S135-S144; Lippincott Williams & Wilkins			
82		ERIK DE CLERCQ; New Developments in Anti-HIV Chemotherapy; Current Medicinal Chemistry (2001) Vol. 8 pages 1543-1572; Bentham Science Publishers Ltd			
,		International Search Report Reference Number PCT/US2004/008764			
	,				

	•••••••				
*************************	***********				
; ;)>>***********************************				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.